These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34491667)

  • 1. Clinical difference between single subtype and mixed subtype chronic urticaria: A retrospective study.
    Mao M; Yuan Y; Xiao Y; Peng C; Chen X; Li J
    Indian J Dermatol Venereol Leprol; 2022; 88(2):171-176. PubMed ID: 34491667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of a chronic urticaria referral university center.
    Andrade Coelho Dias G; Cunha Coelho F; Filippo P; Lacerda Pedrazzi D; Nogueira Arraes AC; Perelló MI; Chigres Kuschnir F; Costa E
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):112-120. PubMed ID: 31287262
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response.
    Curto-Barredo L; Pujol RM; Roura-Vives G; Gimenez-Arnau AM
    Eur J Dermatol; 2019 Dec; 29(6):627-635. PubMed ID: 31903953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic inducible urticaria: confirmation through challenge tests and response to treatment.
    Pereira ARF; Motta AA; Kalil J; Agondi RC
    Einstein (Sao Paulo); 2020; 18():eAO5175. PubMed ID: 32667419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
    Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment.
    Türk M; Yılmaz İ; Nazik Bahçecioğlu S; Can P; Ertaş R; Kartal D; Çınar SL; Kocatürk E
    Dermatol Ther; 2021 Jan; 34(1):e14543. PubMed ID: 33190334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.
    Gastaminza G; Azofra J; Nunez-Cordoba JM; Baeza ML; Echechipía S; Gaig P; García BE; Labrador-Horrillo M; Sala-Cunill A; Brescó MS; Beristain A; Quiñones D; Donado CD; Zubeldia JM; Ferrer M
    J Allergy Clin Immunol Pract; 2019; 7(5):1599-1609.e1. PubMed ID: 30654196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study.
    Savic S; Leeman L; El-Shanawany T; Ellis R; Gach JE; Marinho S; Wahie S; Sargur R; Bewley AP; Nakonechna A; Randall R; Fragkas N; Somenzi O; Marsland A
    Clin Exp Dermatol; 2020 Dec; 45(8):1003-1010. PubMed ID: 32246853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
    Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
    J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
    J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic Dermographism: A Systematic Review of Treatment Options.
    Kulthanan K; Ungprasert P; Tuchinda P; Chularojanamontri L; Rujitharanawong C; Kiratiwongwan R; Jantanapornchai N; Hawro T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3141-3161. PubMed ID: 32473421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of chronic urticaria refractory to antihistamines in Andalucia, Spain.
    Pereyra-Rodriguez JJ; Galán Gutiérrez M; Armario-Hita JC; Ruiz-Villaverde R
    Dermatol Ther; 2020 Nov; 33(6):e13866. PubMed ID: 32558086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.